- Home
- BVC vs RAPP Comparison
BVC vs RAPP Comparison
Compare BVC & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | BVC | RAPP |
|---|---|---|
| Founded | 2019 | 2022 |
| Country | Hong Kong | United States |
| Employees | 6 | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | BVC | RAPP |
|---|---|---|
| Price | $8.54 | $38.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $48.50 |
| AVG Volume (30 Days) | 12.5K | ★ 377.0K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.99 | $13.43 |
| 52 Week High | $15.00 | $43.76 |
Technical Indicators
Market Signals| Indicator | BVC | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 41.02 | 52.71 |
| Support Level | $8.03 | $33.54 |
| Resistance Level | $8.57 | $40.61 |
| Average True Range (ATR) | 1.75 | 2.47 |
| MACD | -0.27 | 0.13 |
| Stochastic Oscillator | 7.45 | 41.23 |
Price Performance
Historical ComparisonAbout BVC BitVentures Limited American Depositary Shares
BitVentures Ltd is a technology-focused company. It is focused on developing technology businesses in verticals including e-commerce, digital assets, and other areas of consumer and enterprise technology. The company identifies and supports technology ventures across these areas.
About RAPP Rapport Therapeutics Inc.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.